Ocular Therapeutix, Inc financial data

Symbol
OCUL on Nasdaq
Location
15 Crosby Drive, Bedford, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 5, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.09K % -2.34%
Quick Ratio 7.41 % -4.88%
Debt-to-equity 45.7 % -31%
Return On Equity -70 % -11.8%
Return On Assets -48 % -27.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 174M shares +11.6%
Common Stock, Shares, Outstanding 173M shares +11.1%
Entity Public Float 1.06B USD +162%
Common Stock, Value, Issued 17K USD +6.25%
Weighted Average Number of Shares Outstanding, Basic 173M shares +4.08%
Weighted Average Number of Shares Outstanding, Diluted 173M shares +4.08%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 56.7M USD -7.26%
Research and Development Expense 172M USD +113%
Selling and Marketing Expense 49.3M USD +27.2%
General and Administrative Expense 57.5M USD +14.1%
Costs and Expenses 285M USD +62.2%
Operating Income (Loss) -228M USD -99.3%
Nonoperating Income (Expense) 11.4M USD +7.49%
Net Income (Loss) Attributable to Parent -217M USD -56.7%
Earnings Per Share, Basic -1 USD/shares -11.7%
Earnings Per Share, Diluted -1 USD/shares -10.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 391M USD -14.9%
Accounts Receivable, after Allowance for Credit Loss, Current 30.4M USD +0.6%
Inventory, Net 3.04M USD +19.3%
Assets, Current 433M USD -13.1%
Property, Plant and Equipment, Net 10.5M USD -3.91%
Operating Lease, Right-of-Use Asset 5.88M USD -2.03%
Assets 451M USD -12.7%
Accounts Payable, Current 5.89M USD +59.6%
Employee-related Liabilities, Current 10.2M USD +20.8%
Accrued Liabilities, Current 34.4M USD +41.3%
Contract with Customer, Liability, Current 64K USD -75.7%
Liabilities, Current 42.9M USD +43.2%
Contract with Customer, Liability, Noncurrent 14M USD 0%
Operating Lease, Liability, Noncurrent 4.41M USD -27.7%
Other Liabilities, Noncurrent 148K USD +29.8%
Liabilities 145M USD +4.32%
Retained Earnings (Accumulated Deficit) -1.02B USD -26.9%
Stockholders' Equity Attributable to Parent 306M USD -19%
Liabilities and Equity 451M USD -12.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -44.7M USD -31.8%
Net Cash Provided by (Used in) Financing Activities 4.18M USD -98.7%
Net Cash Provided by (Used in) Investing Activities -1.93M USD -658%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 173M shares +11.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -42.4M USD -115%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 393M USD -14.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities 2.14M USD -83.5%
Deferred Tax Assets, Valuation Allowance 225M USD +22.6%
Deferred Tax Assets, Gross 229M USD +17.6%
Operating Lease, Liability 7.28M USD -14%
Payments to Acquire Property, Plant, and Equipment 1.93M USD +658%
Lessee, Operating Lease, Liability, to be Paid 8.74M USD -18.4%
Property, Plant and Equipment, Gross 33M USD +3.19%
Operating Lease, Liability, Current 2.63M USD +58.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.09M USD +15.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.72M USD +8.71%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.46M USD -35.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.18M USD -19.6%
Deferred Tax Assets, Operating Loss Carryforwards 135M USD +11.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 750K USD -64.5%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 981K USD +6.63%
Deferred Tax Assets, Net of Valuation Allowance 3.63M USD -66.5%
Share-based Payment Arrangement, Expense 34M USD +20.8%
Interest Expense 13.6M USD +91.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%